Company news

Regenxbio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

February 8, 2022

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

February 8, 2022

REGENXBIO Announces Presentations at the 11th Annual SVB Leerink Global Healthcare Conference

February 7, 2022

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference

February 3, 2022

REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022

January 30, 2022

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

January 9, 2022

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

January 5, 2022

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

November 21, 2021

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021

November 11, 2021

REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie

November 8, 2021

REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting

November 4, 2021

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights

November 1, 2021

REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operational Highlights

October 25, 2021

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting

October 8, 2021

REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting

September 30, 2021

REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting

September 30, 2021

REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call

September 26, 2021

AbbVie and REGENXBIO Announce Eye Care Collaboration

September 12, 2021

Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors

September 6, 2021

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights

August 8, 2021

REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational Highlights

August 1, 2021

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting

May 13, 2021

REGENXBIO to Present at Upcoming Investor Conferences

May 5, 2021

REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights

May 4, 2021

REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights

April 27, 2021

REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting

April 26, 2021

REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

April 20, 2021

REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)

April 13, 2021

REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights

February 28, 2021

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

February 21, 2021

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

February 15, 2021

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021

February 7, 2021

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference

February 4, 2021

REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021

January 31, 2021

REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

January 11, 2021

REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 10, 2021

REGENXBIO Announces Pricing Of Public Offering Of Common Stock

January 7, 2021

REGENXBIO Announces Proposed Public Offering Of Common Stock

January 5, 2021

REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

January 4, 2021

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million

December 21, 2020

REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

December 9, 2020

REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II

December 7, 2020

REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I

November 30, 2020

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting

November 9, 2020

REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights

November 3, 2020

REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights

October 27, 2020

REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG

October 26, 2020

REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

September 29, 2020

REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

September 8, 2020

REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

August 24, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.